Epizyme, Inc. announced that the company has earned a milestone payment worth $6 million from GlaxoSmithKline (GSK - Free Report) .
The payment was triggered by Glaxo’s initiation of a phase I study on GSK3326595 (formerly EPZ015938). The company initiated a phase I dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK3326595 in patients with solid tumors and non-Hodgkin lymphoma.
Epizyme had licensed the candidate to Glaxo. Under the terms of the collaboration agreement, Epizyme granted exclusive worldwide license rights to Glaxo to methyltransferase inhibitors directed at three targets.
While Epizyme was primarily responsible for pre-clinical research, Glaxo is responsible for subsequent research, development and commercialization of the three programs. Epizyme discovered and optimized compounds targeting three methyltransferases, including PRMT5 but Glaxo holds worldwide rights to all three programs. Among these, GSK3326595 is the first to enter the clinical stage.
To date, Epizyme has earned $59 million in up-front, research, and milestone payments. The company is entitled to receive up to an additional $617 million from Glaxo on the achievement of all milestones for all the three programs.
Moreover, Epizyme is eligible to receive up to double-digit royalties on worldwide net sales of the collaboration products.
With no approved product in its kitty as of yet, Epizyme is highly dependent on its collaboration partners for top-line growth. The company’s pipeline is still early stage and several years from commercialization.
Epizyme currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Ligand Pharmaceuticals (LGND - Free Report) and Pacira Pharmaceuticals (PCRX - Free Report) . Both these stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Epizyme, Inc. announced that the company has earned a milestone payment worth $6 million from GlaxoSmithKline (GSK - Free Report) .
The payment was triggered by Glaxo’s initiation of a phase I study on GSK3326595 (formerly EPZ015938). The company initiated a phase I dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK3326595 in patients with solid tumors and non-Hodgkin lymphoma.
Epizyme had licensed the candidate to Glaxo. Under the terms of the collaboration agreement, Epizyme granted exclusive worldwide license rights to Glaxo to methyltransferase inhibitors directed at three targets.
While Epizyme was primarily responsible for pre-clinical research, Glaxo is responsible for subsequent research, development and commercialization of the three programs. Epizyme discovered and optimized compounds targeting three methyltransferases, including PRMT5 but Glaxo holds worldwide rights to all three programs. Among these, GSK3326595 is the first to enter the clinical stage.
To date, Epizyme has earned $59 million in up-front, research, and milestone payments. The company is entitled to receive up to an additional $617 million from Glaxo on the achievement of all milestones for all the three programs.
Moreover, Epizyme is eligible to receive up to double-digit royalties on worldwide net sales of the collaboration products.
With no approved product in its kitty as of yet, Epizyme is highly dependent on its collaboration partners for top-line growth. The company’s pipeline is still early stage and several years from commercialization.
Epizyme currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Ligand Pharmaceuticals (LGND - Free Report) and Pacira Pharmaceuticals (PCRX - Free Report) . Both these stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on GSK - FREE
Get the latest research report on LGND - FREE
Get the latest research report on PCRX - FREE